MedTrace Logo

A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

NCT01223209 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-01-11

No results posted yet for this study

Summary

This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour.

GV1001 is a peptide vaccine in development to treat cancer. An adjuvant, is required to start the immune response in the body to have effect of GV-1001.

LTX-315, also a peptide, in development for cancer treatment. In this study, the investigators wish to find out whether LTX-315 can make GV1001 more effective at stimulating the immune system.

Conditions

  • Carcinoma

Interventions

DRUG

LTX-315

0.25-2.0 mg/ML, maximum 5 injections during 36 days.

Sponsors & Collaborators

  • Kael-GemVax Co., Ltd.

    collaborator INDUSTRY

  • Lytix Biopharma AS

    lead INDUSTRY

Principal Investigators

  • Tone Nordøy, MD, PhD · Tromsø University Hospital

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01223209 on ClinicalTrials.gov